GRPH News and Press, Graphite Bio Inc. From 11/18/21

Graphite Bio Initiated the phase 1/2 CEDAR trial using GPH101 for a potential curative treatment of patients with severe sickle-cell disease. First patient in phase 1/2 CEDAR trial will be dosed in the 1st half of 2022 and the first set of results are expected in the 2nd half of 2022....

Graphite Bio (NASDAQ:GRPH) announces that the first patient has been enrolled in its Phase 1/2 clinical trial of GPH101, an investigational gene-edited autologous hematopoietic stem cell therapy designed to correct the genetic mutation that causes sickle cell disease (SCD). The company expect...

GPH101 designed to directly correct the genetic mutation responsible for sickle cell disease First patient expected to be treated in first half of 2022, with initial proof-of-concept data anticipated by end of 2022 Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage,...

Graphite Bio (NASDAQ:GRPH): Q3 GAAP EPS of -$0.28 in-line. Pres Release. For further details see: Graphite Bio EPS in-line

Recruitment for Phase 1/2 CEDAR clinical trial of GPH101 for sickle cell disease underway at multiple sites Details about CEDAR trial to be presented at 63rd ASH Annual Meeting and Exposition in December $395.0 million in cash, cash equivalents and restricted cash as o...

Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today announced that information about the company’s Phase 1/2 CEDAR trial of GPH101, an invest...

Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, announced today that members of the management team will participate in a fireside chat at the Jefferi...

Data support ability of company’s gene editing platform to precisely and efficiently correct the underlying disease-causing mutation and restore adult hemoglobin expression with curative potential Data show minimal off-target editing using company’s exclusively l...

Gainers: ChemoCentryx (NASDAQ:CCXI) +70%. Renren (NYSE:RENN) +48%. DatChat (NASDAQ:DATS) +32%. ReShape Lifesciences (NASDAQ:RSLS) +29%. Huadi International (NASDAQ:HUDI) +24%. Voyager (NASDAQ:VYGR) +22%. NextPlay Technologies (NASDAQ:NXTP) +21%. Tian Ruixiang (NASDAQ:TIRX) +20%. Lilium (NASDA...

Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today announced an abstract related to the company’s sickle cell disease (SCD) research has bee...